Nalpain (Nalbuphine Hydrochloride)

Nalpain (nalbuphine hydrochloride) is used in clinical settings to manage pain through its action on opioid receptors.

• Postoperative pain: Provides effective analgesia for moderate to severe pain following surgical procedures.
• Acute trauma pain: Controls pain associated with injuries such as fractures or burns.
• Obstetric analgesia: Used to relieve labor pain while maintaining maternal and fetal safety.
• Cancer-related pain: Offers analgesic relief for patients with malignant disease when other opioids are insufficient.
• Visceral pain: Reduces intense abdominal or pelvic pain that does not respond well to conventional opioids.

• Nalbuphine hydrochloride acts as a mixed opioid receptor modulator. It binds with high affinity to kappa (κ) opioid receptors as an agonist, producing analgesia, while simultaneously antagonizing mu (μ) opioid receptors, which limits typical mu‑mediated side effects such as respiratory depression and euphoria. This dual activity results in effective pain relief with a ceiling effect on certain adverse effects. The overall pharmacologic profile contributes to a favorable safety profile in clinical use.

Nalbuphine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Vomiting: occasional episodes.
• Dizziness: transient light‑headedness.
• Sedation: drowsiness or reduced alertness.
• Pruritus: itching, especially at injection site.
• Sweating: increased perspiration.

Serious or Rare Side Effects

• Respiratory depression: reduced breathing effort, potentially life‑threatening.
• Hypotension: significant drop in blood pressure.
• Bradycardia: abnormally slow heart rate.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Seizures: rare convulsive events.

When using Nalpain, clinicians should observe specific precautions to ensure patient safety and maintain drug integrity.

• Patient assessment: evaluate pain level, opioid tolerance, and medical history before initiating therapy.
• Respiratory monitoring: observe for signs of respiratory depression, especially in opioid‑naïve patients.
• Concomitant CNS depressants: avoid or use with caution when combined with alcohol, benzodiazepines, or other sedatives.
• Renal or hepatic impairment: adjust dosing and monitor closely in patients with liver or kidney dysfunction.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nalbuphine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Opioid antagonists (e.g., naloxone, naltrexone): may reverse analgesic effect and precipitate withdrawal.
• CNS depressants (e.g., barbiturates, high‑dose benzodiazepines): can enhance sedation and respiratory depression.
• MAO inhibitors: concurrent use may increase risk of severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Other opioids: additive effects may increase sedation and respiratory compromise.
• Anticholinergic agents: may exacerbate constipation and urinary retention.
• CYP3A4 inhibitors/inducers: may affect nalbuphine metabolism, requiring dose adjustment.